• Amikacin (BAY416651): Innovations in Targeted Antibiotic Res

  2026-06-03

  Explore Amikacin (BAY416651) as a bacterial protein synthesis inhibitor, with a focus on novel targeted delivery methods and resistance mechanisms. Uncover practical assay insights and research applications that advance antibiotic resistance studies.

• Acetylation-Regulated Spliceosome Alters PARP Inhibitor Sens

  2026-06-03

  This study uncovers the pivotal role of SmD2 acetylation in modulating DNA repair and response to PARP inhibitors in hepatocellular carcinoma (HCC). The findings suggest that targeting spliceosome regulation and protein acetylation could broaden therapeutic options, especially for BRCA1/2-proficient HCC.

• E-4031: hERG Potassium Channel Blocker in Cardiac Research

  2026-06-02

  E-4031 is the gold-standard hERG potassium channel blocker for modeling proarrhythmic substrates, QT interval prolongation, and torsades de pointes (TdP) in cardiac electrophysiology research. Explore best-practice protocols, troubleshooting, and how APExBIO’s high-purity E-4031 advances assay reproducibility and translational insight.

• Cy5-UTP in RNA Labeling: Protocols, Use-Cases & Innovations

  2026-06-02

  Cy5-UTP (Cyanine 5-UTP) transforms RNA labeling workflows by enabling direct, high-sensitivity probe visualization and precise multiplexing. This guide translates reference-driven insights and bench-tested protocol enhancements into actionable steps for molecular biologists tackling advanced RNA analysis.

• Losmapimod (GW856553X): Optimizing Inflammation and Vascular

  2026-06-01

  Losmapimod (GW856553X) sets a benchmark for selective and dual-action p38 MAPK inhibition, enabling high-fidelity modulation of inflammation and vascular function in both cellular and animal models. This article details actionable protocol enhancements, practical troubleshooting, and the translational impact of recent mechanistic breakthroughs—empowering researchers with reproducible, data-driven solutions.

• Biotin-16-UTP: Technical Guide for RNA Labeling Workflows

  2026-06-01

  Biotin-16-UTP addresses the need for efficient, specific biotin labeling of RNA during in vitro transcription, enabling robust RNA detection, purification, and interaction studies. It is best used in workflows requiring high-affinity biotin-streptavidin interactions, but is not suitable for diagnostic or therapeutic applications.

• EZ Cap™ Human PTEN mRNA (ψUTP): Applied Workflows & Troubles

  2026-05-31

  EZ Cap™ Human PTEN mRNA (ψUTP) transforms cancer research by enabling robust PTEN re-expression with enhanced stability and low immunogenicity. Explore stepwise protocols, troubleshooting insights, and the latest nanoparticle delivery innovations for effective PI3K/Akt pathway inhibition.

• RIN3-BIN1 Disruption Drives RAB5 Hyperactivation in Alzheime

  2026-05-30

  This study uncovers how mutations in RIN3 disrupting its interaction with BIN1 lead to RAB5 hyperactivation and endosomal abnormalities, key features of early Alzheimer’s disease (AD) pathology. The work clarifies the mechanistic link between two major AD risk genes and highlights the importance of endosomal trafficking in disease initiation.

• Redefining mRNA Tracking: Dual-Reporter Tools Meet Advanced

  2026-05-29

  This thought-leadership article examines the transformative role of dual-reporter mRNA systems—specifically EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP)—in overcoming translational research bottlenecks in delivery, imaging, and immunogenicity. Leveraging mechanistic advances in mRNA engineering and referencing recent breakthroughs in virus-mimicking nanocarriers, we offer strategic guidance for researchers striving for reliable, immune-silent, and multiplexed mRNA assays. The discussion bridges recent literature with practical workflow recommendations, and positions APExBIO’s platform as a key enabler for reproducible, high-impact mRNA research.

• Tunable Human Intestinal Organoids: Balancing Self-Renewal a

  2026-05-29

  This study introduces a tunable human intestinal organoid system that achieves a controlled balance between stem cell self-renewal and differentiation, enabling both high proliferative capacity and cellular diversity under a single culture condition. These advances support scalable, high-throughput research and address key limitations of previous organoid models.

• ALDOB K87 Lactylation Drives Mitochondrial Fission in PH

  2026-05-28

  This study identifies ALDOB K87 lactylation as a critical regulator of mitochondrial fission and metabolic reprogramming in pulmonary hypertension (PH). By dissecting the lactate–ALDOB–DRP1 signaling axis, the research offers significant mechanistic insight into pulmonary vascular remodeling and highlights new avenues for targeted intervention.

• Lung-Targeted Risedronate Sodium Delivery Improves Osteoporo

  2026-05-28

  This study introduces a lung-targeted nano-delivery system for Risedronate Sodium and vitamin D₃ using PAMAM-G5 dendrimers, dramatically enhancing bioavailability and therapeutic efficacy in osteoporosis models. The approach surmounts oral delivery limitations and provides new insights into bone metabolism regulation, with implications for translational bone research.

• Atorvastatin in Cellular Ferroptosis: New Paradigms in HMG-C

  2026-05-27

  Explore how Atorvastatin, a leading HMG-CoA reductase inhibitor, is advancing cholesterol metabolism research and pioneering ferroptosis-based strategies in hepatocellular carcinoma and vascular biology. This article delivers a unique, mechanistic perspective for researchers seeking deeper insights.

• Optimizing Protein Labeling with Cy5 Maleimide (Non-sulfonat

  2026-05-27

  This article addresses common laboratory challenges in fluorescent protein labeling and assay reproducibility, focusing on the application of Cy5 maleimide (non-sulfonated, SKU A8139). Scenario-driven Q&As provide actionable insights and evidence-based recommendations for achieving reliable, site-specific cysteine labeling in cell viability and imaging experiments.

• Dual-Action Kinase Inhibitors Accelerate p38α MAPK Dephospho

  2026-05-26

  The reference study uncovers that certain kinase inhibitors not only block p38α MAPK activity but also promote its dephosphorylation by favoring conformations accessible to phosphatases. This dual-action mechanism offers new possibilities for designing highly specific inhibitors relevant to inflammation and apoptosis research.

15906 records 1/1061 page Next 12345 下5页 Last page